Condition: Malignant Pleural Mesothelioma (MPM) · Sponsor: Azienda USL Reggio Emilia - IRCCS
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of prognostic biomarkers further complicates the decision-making. Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients. Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life expectancy and quality of life of patients with MPM. This study aims to characterize the organization of the immune system infiltrating mesothelioma and the dynamics of its interaction with the tumor. The rationale is that deciphering this complexity will help improve our understanding of the mechanisms underlying this disease and provide a new tool to optimize the use of ICIs in these patients.
This description comes directly from the study's public registry record.
Alessia Ciarrocchi, PhD · 0522/295668 · alessia.ciarrocchi@ausl.re.it
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliera Universitaria Policlinico Rodolico San Marco di Catania | Catania, Italy | Recruiting |
| Azienda Ospedaliera Universitaria Luigi Vanvitelli, Napoli | Naples, Italy | Recruiting |
| Azienda USL IRCCS di Reggio Emilia | Reggio Emilia, Italy | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07561190